JAK2 and myeloproliferative disorder: Prestipino et al. discovered that mice models with JAK2‐V617F mutated MPN generally have an increased expression of programmed death‐ligand 1 (PD‐L1) that leads to cancer immune evasion by inhibiting the antitumor effect of the T lymphocytes against cancer cells.7